Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.

Published

Journal Article

RNA editing in mammals is a form of post-transcriptional modification in which adenosine is converted to inosine by the adenosine deaminases acting on RNA (ADAR) family of enzymes. Based on evidence of altered ADAR expression in epithelial ovarian cancers (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in ADAR genes modify EOC susceptibility, potentially by altering ovarian tissue gene expression. Using directly genotyped and imputed data from 10,891 invasive EOC cases and 21,693 controls, we evaluated the associations of 5,303 SNPs in ADAD1, ADAR, ADAR2, ADAR3, and SND1. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI), with adjustment for European ancestry. We conducted gene-level analyses using the Admixture Maximum Likelihood (AML) test and the Sequence-Kernel Association test for common and rare variants (SKAT-CR). Association analysis revealed top risk-associated SNP rs77027562 (OR (95% CI)= 1.39 (1.17-1.64), P=1.0x10-4) in ADAR3 and rs185455523 in SND1 (OR (95% CI)= 0.68 (0.56-0.83), P=2.0x10-4). When restricting to serous histology (n=6,500), the magnitude of association strengthened for rs185455523 (OR=0.60, P=1.0x10-4). Gene-level analyses revealed that variation in ADAR was associated (P<0.05) with EOC susceptibility, with PAML=0.022 and PSKAT-CR=0.020. Expression quantitative trait locus analysis in EOC tissue revealed significant associations (P<0.05) with ADAR expression for several SNPs in ADAR, including rs1127313 (G/A), a SNP in the 3' untranslated region. In summary, germline variation involving RNA editing genes may influence EOC susceptibility, warranting further investigation of inherited and acquired alterations affecting RNA editing.

Full Text

Duke Authors

Cited Authors

  • Permuth, JB; Reid, B; Earp, M; Chen, YA; Monteiro, ANA; Chen, Z; AOCS Study Group, ; Chenevix-Trench, G; Fasching, PA; Beckmann, MW; Lambrechts, D; Vanderstichele, A; Van Niewenhuyse, E; Vergote, I; Rossing, MA; Doherty, JA; Chang-Claude, J; Moysich, K; Odunsi, K; Goodman, MT; Shvetsov, YB; Wilkens, LR; Thompson, PJ; Dörk, T; Bogdanova, N; Butzow, R; Nevanlinna, H; Pelttari, L; Leminen, A; Modugno, F; Edwards, RP; Ness, RB; Kelley, J; Heitz, F; Karlan, B; Lester, J; Kjaer, SK; Jensen, A; Giles, G; Hildebrandt, M; Liang, D; Lu, KH; Wu, X; Levine, DA; Bisogna, M; Berchuck, A; Cramer, DW; Terry, KL; Tworoger, SS; Poole, EM; Bandera, EV; Fridley, B; Cunningham, J; Winham, SJ; Olson, SH; Orlow, I; Bjorge, L; Kiemeney, LA; Massuger, L; Pejovic, T; Moffitt, M; Le, N; Cook, LS; Brooks-Wilson, A; Kelemen, LE; Gronwald, J; Lubinski, J; Wentzensen, N; Brinton, LA; Lissowska, J; Yang, H; Hogdall, E; Hogdall, C; Lundvall, L; Pharoah, PDP; Song, H; Campbell, I; Eccles, D; McNeish, I; Whittemore, A; McGuire, V; Sieh, W; Rothstein, J; Phelan, CM; Risch, H; Narod, S; McLaughlin, J; Anton-Culver, H; Ziogas, A; Menon, U; Gayther, S; Ramus, SJ; Gentry-Maharaj, A; Pearce, CL; Wu, AH; Kupryjanczyk, J; Dansonka-Mieszkowska, A; Schildkraut, JM; Cheng, JQ; Goode, EL; Sellers, TA

Published Date

  • November 8, 2016

Published In

Volume / Issue

  • 7 / 45

Start / End Page

  • 72381 - 72394

PubMed ID

  • 27911851

Pubmed Central ID

  • 27911851

Electronic International Standard Serial Number (EISSN)

  • 1949-2553

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.10546

Language

  • eng

Conference Location

  • United States